Abstract:
Background:The global Phase III LUX-Lung 8 trial (ClinicalTrials.gov: NCT01523587) identified significant improvements in progression-free survival (PFS), overall survival (OS), and patient-reported outcomes (PROs) with second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung. Materials and methods:We conducted a post hoc analysis of data for patients in LUX-Lung 8 from mainland China (n=67). Compared with erlotinib, afatinib reduced the risk of disease progression or death (PFS) in the Chinese subgroup by 30% (HR=0.70; 95% CI: 0.38-1.27). Results:The risk of death was reduced by 31% (HR=0.69; 95% CI: 0.39-1.21). The proportion of Chinese patients with improvements in PROs also favored afatinib vs erlotinib (global health status/quality of life [QoL], 52.8% vs 29.6%, P=0.072; dyspnea, 47% vs 26%, P=0.091; "dyspnea walked", 44% vs 15%, P=0.017; QoL rate, 53% vs 26%, P=0.037). Discussion:While this analysis was not powered to demonstrate differences compared to the overall trial population (OTP), and there were some differences in baseline characteristics (eg, the proportion of patients aged ≥65 years old), the benefits of afatinib treatment in Chinese patients with SCC of the lung appeared to be at least comparable to that observed in LUX-Lung 8. As with the OTP, the most common adverse events (AEs) with afatinib in the Chinese subgroup were diarrhea and rash/acne, and the incidence and type of the most frequently occurring AEs were similar. Conclusion:The results suggest that afatinib represents a feasible treatment option for Chinese patients with advanced SCC of the lung following progression on platinum-based chemotherapy.
journal_name
Onco Targets Therjournal_title
OncoTargets and therapyauthors
Lu S,Li W,Zhou C,Hu CP,Qin S,Cheng G,Feng J,Wang J,Cseh A,Peil B,Gibson N,Ehrnrooth E,Zhang Ldoi
10.2147/OTT.S161506subject
Has Abstractpub_date
2018-11-30 00:00:00pages
8565-8573issn
1178-6930pii
ott-11-8565journal_volume
11pub_type
杂志文章abstract:Introduction:Melanoma is a common skin cancer that is usually associated with poor clinical outcomes. Recently, the immune checkpoint GITR has been identified as a promising target for immunotherapy of melanoma. In this study, we aimed to investigate the post-translational regulation mechanism of GITR in melanoma. Met...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S212317
更新日期:2019-12-04 00:00:00
abstract:OBJECTIVE:To evaluate the efficacy and safety of bortezomib-based vs non-bortezomib-based post-transplantation therapy in patients with multiple myeloma. METHODS:Data of relevant randomized controlled trials assessing the effect of bortezomib as post-transplantation consolidation or maintenance therapy was obtained th...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S84828
更新日期:2015-06-15 00:00:00
abstract:Background:Long non-coding RNAs (lncRNAs) have been verified to have a vital role in the progression of glioblastoma multiforme (GBM). Our research was about to identify the potential lncRNAs which was closely associated with the pathogenesis and prognosis of glioblastoma multiforme. Methods:All RNA sequence profiling...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S235951
更新日期:2020-02-04 00:00:00
abstract:AIM:To investigate the clinical significance of cyclic adenosine monophosphate-responsive element-binding (CREB) and phosphorylated CREB (pCREB) expression in human hepatocellular carcinoma (HCC). MATERIALS AND METHODS:Immunohistochemistry and Western blot analyses were performed to detect the expression and subcellul...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S63594
更新日期:2014-05-29 00:00:00
abstract:Background:LncRNA EMX2OS (EMX2 opposite strand/antisense RNA) is notably downregulated in prostate cancer (PCa) tissues and may be regarded as a potential molecular biomarker for diagnosis and prognosis. However, its exact role in regulating the development of PCa is obscure. Methods:The EMX2OS expression was assessed...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S243552
更新日期:2020-07-21 00:00:00
abstract:Background:The aberrant expression of circular RNAs (circRNAs) has been identified as a novel trait of cancers. However, the role of circRNAs in colorectal cancer (CRC) remains to be elucidated. Methods:Informatic analysis was performed to identify circRNAs in CRC tissues and adjacent tissues. Gain- and loss-of-functi...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S255485
更新日期:2020-06-30 00:00:00
abstract::[This corrects the article DOI: 10.2147/OTT.S196910.]. ...
journal_title:OncoTargets and therapy
pub_type: 已发布勘误
doi:10.2147/OTT.S229714
更新日期:2019-09-19 00:00:00
abstract:Introduction:Forkhead box (FOX) superfamily members were recently shown to play important roles in tumor development and progression. Forkhead box S1 (FOXS1), a member of the FOX family, has been reported to be closely associated with malignant neoplasms. However, its expression and effect on hepatocellular carcinoma r...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S272596
更新日期:2020-11-17 00:00:00
abstract::[This retracts the article on p. 1997 in vol. 9, PMID: 27103825.][This retracts the article on p. 841 in vol. 28.]. ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,撤回出版物
doi:10.2147/OTT.S121862
更新日期:2016-09-20 00:00:00
abstract::The mortality of hepatobiliary cancer still stays high around the world, with disappointing treatment status at advanced stage. Genomic analysis has identified the global spectrum of alterations in liver cancer, but the most common mutations are not actionable, meanwhile lacking potent molecular-targeted drugs for spe...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S223568
更新日期:2019-11-19 00:00:00
abstract::Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by an increased risk of thrombosis and progression to acute myeloid leukemia. MPN are associated with driver mutations in JAK2, CALR and MPL which are crucial for the ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S287944
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Two types of epidermal growth factor receptor (EGFR) mutations in exon 19 and exon 21 (ex19del and L858R) are prevalent in lung cancer patients and sensitive to targeted EGFR inhibition. A resistance mutation in exon 20 (T790M) has been found to accompany drug treatment when patients relapse. These three mut...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S84938
更新日期:2015-06-22 00:00:00
abstract::POEMS syndrome (acronym consisting of: polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) is an uncommon disorder associated with an underlying plasma cell dyscrasia. There is no single specific test for POEMS, and due to its rarity and heterogeneity, patients are often mis- or underdiagnosed. ...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S146221
更新日期:2018-09-27 00:00:00
abstract:Background:Renal cell cancer (RCC) is one of the most lethal malignancies of the kidney in adults. mTOR (mammalian target of rapamycin) signaling pathway plays a pivotal role in RCC tumorigenesis and progression and inhibitors targeting the mTOR pathway have been widely used in advanced RCC treatment. Therefore, it is ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S266095
更新日期:2020-10-15 00:00:00
abstract:AIMS:Metastasis-associated gene 2 (MTA2) is reported to play an important role in tumor progression, but little is known about the role of MTA2 in nasopharyngeal carcinoma (NPC). The aim of the study was to explore the expression and function of MTA2 in NPC. METHODS:Expression of MTA2 in NPC tissues and cell lines was...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S96518
更新日期:2016-03-18 00:00:00
abstract::Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both early and metastatic HE...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S27733
更新日期:2013-01-01 00:00:00
abstract:Objective:To clarify the role and mechanism of GABPB1-AS1 in renal cell carcinoma. Methods:We collected 48 pairs of tumor and adjacent normal tissues from patients with clear cell renal cell carcinoma (ccRCC). Both 786-o and caki-1 ccRCC cell lines were transfected with GA-binding protein transcription factor subunit ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S257275
更新日期:2020-07-12 00:00:00
abstract:BACKGROUND:Primary angiosarcoma of breast (PAOB) is a rare and highly aggressive malignancy. There is no general agreement on optimal treatments or prognostic factors for this orphan disease. The objective of this study was to investigate the clinicopathologic features and management experiences of PAOB. METHODS:We pe...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S92769
更新日期:2015-11-04 00:00:00
abstract:Background:Several EGFR-tyrosine kinase inhibitors (TKIs), such as gefitinib (Gef), have been used as effective clinical therapies for patients with non-small cell lung cancer (NSCLC). However, due to acquired resistance, the efficacy of Gef treatment is severely blocked. Our preliminary study found that epigallocatech...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S209441
更新日期:2019-07-26 00:00:00
abstract::Purpose: NSD3 (WHSC1L1) is a protein lysine methyltransferase that is recurrently amplified (8p11.23) in several cancer types, and its upregulation is involved in tumor cell proliferation, metastasis, and epithelial-mesenchymal transition (EMT). We aimed to evaluate its potential function as an oncogenic force in colo...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S191732
更新日期:2019-05-21 00:00:00
abstract:OBJECTIVES:The long-noncoding RNAs (lncRNAs) are identified as new crucial regulators of diverse cellular processes in glioblastoma (GBM) tissues. However, the expression pattern and biological function of lncRNAs remain largely unknown. Here, for the first time, the effects of lncRNA lymphoid enhancer-binding factor 1...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S130365
更新日期:2017-08-28 00:00:00
abstract:Background:KIF18B was identified as a potential oncogene by analysis of The Cancer Genome Atlas database. Materials and methods:We assessed KIF18B expression and explored its clinical significance in cervical cancer tissues. We have also evaluated the effects of KIF18B on cervical cancer cell proliferation, migration,...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S157440
更新日期:2018-03-28 00:00:00
abstract:BACKGROUND:Forkhead box Q1 (FOXQ1, also known as HFH1), a member of the forkhead transcription factor family, has been demonstrated to be overexpressed in multiple tumors and is thought to be an indicator of poor clinical outcomes. METHODS:A meta-analysis using qualified relevant literature was performed to evaluate t...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S130905
更新日期:2017-03-23 00:00:00
abstract::Lung cancer is the leading cause of cancer-related mortality in both sexes, accounting for over one quarter of cancer deaths. Non-small-cell lung cancer (NSCLC) comprises 85%-90% of lung cancer diagnoses and despite advances in multimodality therapies, 5-year survival rates remain dismal with a median survival for pat...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S67262
更新日期:2015-04-20 00:00:00
abstract:Purpose:FAM110B is a member of the FAM110 family (family with sequence similarity 110), which is a component of the centrosome associated proteins. Previous studies have shown that FAM110B may be involved in the process of cell cycle and may play a role in carcinogenesis and tumor progression. Using an online database,...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S247491
更新日期:2020-05-19 00:00:00
abstract:OBJECTIVE:High-mobility group protein 2 (HMGA2) and epithelial-mesenchymal transition (EMT)-associated proteins play key roles in cancer progression and metastasis. However, the clinical significance of HMGA2 and its relationship with EMT markers in nasopharyngeal carcinoma (NPC) is unclear. This study aimed to assess ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S74397
更新日期:2015-01-17 00:00:00
abstract::The chemokine receptor 4/chemokine ligand 12 (CXCR4/CXCL12) axis plays an important role in tumorigenesis, metastasis, and recurrence of tumors. Its single nucleotide polymorphisms (SNPs) are associated with patient survival in several types of cancer. However, the prognostic value of SNPs in nasopharyngeal carcinoma ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S90430
更新日期:2015-10-08 00:00:00
abstract:Background and aim:Studies suggest that antiviral therapy performed after curative resection improves the postoperative prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), but the evidence has been contradictory. The aim of this meta-analysis was to assess the effect of antiviral therapy with n...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S150281
更新日期:2017-11-10 00:00:00
abstract::CD47 belongs to immunoglobulin superfamily and is widely expressed on the surface of cell membrane, while another transmembrane protein SIRPα is restricted to the surface of macrophages, dendritic cells, and nerve cells. As a cell surface receptor and ligand, respectively, CD47 and SIRPα interact to regulate cell migr...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S249822
更新日期:2020-09-22 00:00:00
abstract::Ewing's sarcoma is a rare and highly aggressive cancer most frequently arising in people under 20 years of age. We report an uncommon case of primary paraesophageal Ewing's sarcoma in a 25-year-old male harboring the infrequent EWSR1/ERG fusion transcript with multiple splice variants coexisting in the same tumor. The...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S80879
更新日期:2015-05-14 00:00:00